ABEO vs UNH

Abeona Therapeutics maintains high 10x potential, primarily driven by its first-in-class FDA-approved gene therapy, ZEVASKYN, for the ultra-rare RDEB, establishing a significant regulatory moat in a market with critical unmet needs. The substantial cash position of $191.4M provides a crucial runway for commercialization. While Q4 2025 results confirmed a slow commercial ramp ($5.4M revenue miss, $...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...